Natural progression of patients with Parkinson disease on less pulsatile levodopa therapy
Objective: To evaluate the natural progression of Parkinson disease (PD) in patients on less pulsatile levodopa therapy (LPT). Background: Previously we have shown that patients…Levodopa-induced unilateral orofacial dystonia in multiple system atrophy : case report and video presentation
Objective: The study reports a case of lateral orofacial dystonia in a multiple system atrophy (MSA) patient treated with levodopa, and discusses the clinical characteristics…Dyskinesia profiles after dose challenges with L-dopa vs L-dopa plus ropinirole: a pilot study
Objective: To investigate possible differences in the profiles of abnormal involuntary movements (AIMs) in patients with Parkinson’s disease (PD) after dose challenge with L-dopa alone…Amelioration of Levodopa-induced Dyskinesias using Genetic Silencing of Striatal CaV1.3 in Parkinsonian Rats: Impact of Sex and Advancing Age
Objective: To advance understanding of striatal CaV1.3 (cacna1d) channel silencing as a therapeutic approach to reduce levodopa-induced dyskinesias (LID), a side effect of long-term escalating…Effect of the mGlu2/3 orthosteric agonist LY-404,039 on dyskinesia, psychosis-like behaviours, and parkinsonism in the MPTP-lesioned marmoset
Objective: To assess the effect of LY-404,039 on dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset model of Parkinson’s disease (PD). Background:…A dose-response study of the effect of the mGlu2/3 orthosteric antagonist LY-341,495 on the anti-dyskinetic and anti-psychotic effect of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset
Objective: To assess the effects of different doses of the metabotropic glutamate 2 and 3 (mGlu2/3) orthosteric antagonist (OA) LY-341,495 on the anti-dyskinetic and anti-psychotic…Antidyskinetic Effects of CaV1.3 Calcium Channel Gene Silencing in Aged Male and Female Parkinsonian Macaques
Objective: To determine whether striatal CaV1.3 gene silencing ameliorates levodopa-induced dyskinesias (LID) in the preclinical gold-standard non-human primate (NHP) model without altering levodopa’s antiparkinsonian benefit.…Should Amantadine DR/ER Be Considered Prior to Device-Aided Therapies for Parkinson’s Disease?
Objective: Evaluate delayed release/extended release amantadine (AMT DR/ER) capsules for motor complications in patients meeting 5-2-1 criteria for device-aided therapies (DAT) in advanced Parkinson disease.…Early-onset vs. Late-onset Parkinson’s disease
Objective: To determine the clinical and therapeutic peculiarities that distinguish Early onset Parkinson’s disease (EOPD) from late onset Parkinson’s disease (LOPD). Background: Age is the…Amantadine DR/ER-Related Reduction in OFF and Dyskinesia Improved Patient-Rated Interference with Activities and Social Interactions
Objective: Evaluate dyskinesia and OFF interference with activities and experiences for persons with Parkinson disease (PWPD), and mitigation with treatment Background: OFF and Dyskinesia remain…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 49
- Next Page »